Ovarian Cancer :: New Therapy for Patients with Platinum-Resistant Ovarian Cancer
Mayo Clinic reported promising interim results from a Phase II trial of a new combination therapy for patients with recurrent ovarian cancer that is resistant to platinum therapy. Thirty-three percent of study participants achieved either complete or partial tumor regression from the therapy, which combines flavopiridol and cisplatin.